General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,035,910 shares of the company's stock, valued at approximately $11,405,000. Maze Therapeutics accounts for approximately 1.3% of General Catalyst Group Management LLC's investment portfolio, making the stock its 8th biggest position. General Catalyst Group Management LLC owned 2.37% of Maze Therapeutics as of its most recent SEC filing.
Analysts Set New Price Targets
Several analysts have commented on MAZE shares. JPMorgan Chase & Co. started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective on the stock. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Guggenheim restated a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Finally, Leerink Partners assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "outperform" rating and a $28.00 target price for the company. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Maze Therapeutics has a consensus rating of "Buy" and an average target price of $25.67.
Read Our Latest Analysis on MAZE
Maze Therapeutics Stock Performance
Shares of MAZE traded down $0.09 during trading hours on Monday, hitting $13.31. 62,569 shares of the stock were exchanged, compared to its average volume of 224,913. The stock has a 50-day moving average price of $10.13. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Maze Therapeutics Company Profile
(
Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Recommended Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
